Puretech Health Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Puretech Health Plc (PRTC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Puretech Health Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 5M vs 104,203M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs accelerating (+16.5%) for its tracked peer group.
- Growth: Puretech Health Plc generated -3.5% revenue growth year over year in Q4 2025, vs 12.5% for its competitors combined.
- Profitability: Its -2,362.8% net margin compares with 12.8% for the peer group.
- Peer revenue share: Puretech Health Plc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.04M compares with $1.15M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
PRTC Sales vs. its Competitors, Q4 2025
Puretech Health Plc reported revenue contraction of 3.50 % year on year in Q4 2025, below its competitors' combined revenue growth of 12.50 %.
With a net margin of -2,362.82 %, Puretech Health Plc reported lower profitability than its competitors (12.75 %).
Puretech Health Plc generated 0.02 % of the combined sales of its peer group, up from 0.02 % a year earlier.
API endpoints for this dataset
Puretech Health Plc vs. its Competitors, Q4 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Puretech Health Plc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Puretech Health Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Puretech Health Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Puretech Health Plc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs -3.5% for Puretech Health Plc. Puretech Health Plc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Puretech Health Plc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Puretech Health Plc | - | No | No | Yes |
| Competitors combined (40) | ||||
| High-Confidence Competitors (11) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PRTC Stock Performance relative to its Competitors
PRTC Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Verona Pharma Plc | 282.9% | Outperformed |
| 2 | Day One Biopharmaceuticals Inc | 282.9% | Outperformed |
| 3 | Shattuck Labs Inc | 282.9% | Outperformed |
| 4 | Viatris Inc | 282.9% | Outperformed |
| 5 | Jazz Pharmaceuticals Plc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Puretech Health Plc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Puretech Health Plc's Comment on Competition and Industry Peers
Publicly Traded Peers of Puretech Health Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Puretech Health Plc |
423.91 | 4.66 |
 Amgen Inc |
254,015.58 | 38,903.00 |
 Vertex Pharmaceuticals Inc |
140,582.02 | 12,951.60 |
 Argenx Se |
63,537.93 | 8,399.37 |
 Teva Pharmaceutical Industries Limited |
50,833.51 | 14,020.00 |
 Viatris Inc |
23,836.02 | 14,737.30 |
| SUBTOTAL | 616,183.48 | 105,176.72 |
Sign in to see all competitors of Puretech Health Plc.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Puretech Health Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Puretech Health Plc's Competitors Named by the Company
Competitive relationships identified from Puretech Health Plc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| BMS | Company report | 85% |
| Boehringer Ingelheim | Company report | 85% |
| Genentech | Company report | 85% |
| Merck | Company report | 85% |
| Amgen | Company report | 85% |
| Senstar Technologies Corporation | Company report | 85% |
| JnJ | Company report | 85% |
| Cardiol Therapeutics | Company report | 85% |
| Portage Biotech Inc | Company report | 85% |
| Fibrogen | Company report | 85% |
| United Therapeutics | Company report | 85% |
| Jazz Pharmaceuticals | Company report | 85% |
| Sage Therapeutics | Company report | 85% |
| Zynerba Pharmaceuticals | Company report | 85% |
| Emerald Health Pharmaceuticals | Company report | 85% |
| Theralymph | Company report | 85% |
| Marinus Pharmaceuticals | Company report | 85% |
| Celltaxis | Company report | 85% |
| Herantis Pharma | Company report | 85% |
| PHARMENTERPRISES | Company report | 85% |
Company report basis, confidence, active dates and source counts for Puretech Health Plc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Puretech Health Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Teva Pharmaceutical Industries Limited | United States 42.55 % |
| Viatris Inc | Developed Markets 59.34 % |
| Biomarin Pharmaceutical Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Puretech Health Plc.
Puretech Health Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Puretech Health Plc | 424 | 39,483 | -932,915 |
| Amgen Inc | 254,016 | 2,992,538 | 722,385 |
| Vertex Pharmaceuticals Inc | 140,582 | 31,979,259 | 9,817,037 |
| Argenx Se | 63,538 | 7,316,521 | 1,125,466 |
| Teva Pharmaceutical Industries Limited | 50,834 | 412,960 | 14,963 |
| Viatris Inc | 23,836 | 491,243 | -13,690 |
| PEERS TOTAL | 615,760 | 1,148,267 | 164,509 |
Sign in to see all peers for Puretech Health Plc.
Puretech Health Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
| Jazz Pharmaceuticals Plc | United States 88.39 % |
| Therapeuticsmd Inc | Non Us 66.30 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Puretech Health Plc's Position in Industry Market Structure
Market-capitalization share and concentration across all 492 companies in Puretech Health Plc's industry classification, broader than the peer set above. Market cap in millions of $.Puretech Health Plc ranks #0 of 492 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 975, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,261,743 | 23.62 % |
| 2 | Johnson and Johnson | 688,377 | 12.89 % |
| 3 | Abbvie Inc | 519,434 | 9.73 % |
| 4 | Merck and Co Inc | 367,314 | 6.88 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Puretech Health Plc | 476 | 0.00 % |
Market cap and industry share for the rest of Puretech Health Plc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-07-17.
Puretech Health Plc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (445 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 37.84 % (avg) | -37.8 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -6.50 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 0.13 % | 7.56 % (avg) | -7.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Puretech Health Plc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | -78.68 % | 44.98 % | -3.50 % |
| Operating Margin | - | - | - |
| Return on Invested Capital | -13.06 % | -13.83 % | -12.24 % |
| P/E | - | 10.0x | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Puretech Health Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 975 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.13 % vs industry average 7.56 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Puretech Health Plc's dedicated Suppliers and Customers pages, not here.
Puretech Health Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
- Return on equity 56.1 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (55.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Puretech Health Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Puretech Health Plc | 5.45 | 6.59 | - |
| Amgen Inc | 0.49 | 1.31 | 5.27 |
| Vertex Pharmaceuticals Inc | 1.30 | 2.83 | 0.06 |
| Argenx Se | 2.64 | 5.23 | - |
| Teva Pharmaceutical Industries Limited | 0.26 | 0.96 | 2.09 |
| Viatris Inc | 0.18 | 1.47 | 0.96 |
Sign in to see all peers for Puretech Health Plc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Puretech Health Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Puretech Health Plc | Q4 2025 | -3.5 % | - |
| Amgen Inc | Q3 2026 | +8.5 % | +20.1 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +11.8 % | -39.6 % |
| Argenx Se | Q4 2025 | +89.1 % | +55.1 % |
| Teva Pharmaceutical Industries Limited | Q3 2026 | -1.9 % | -46.3 % |
| Viatris Inc | Q2 2026 | +4.9 % | - |
| PEERS TOTAL | +20.6 % | +19.4 % |
Sign in to see all peers for Puretech Health Plc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Puretech Health Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Puretech Health Plc | Q4 2025 | - | -45.5 % |
| Amgen Inc | Q3 2026 | -9.5 % | +34.6 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +26.8 % | -4.4 % |
| Argenx Se | Q4 2025 | +44.6 % | +242.3 % |
| Teva Pharmaceutical Industries Limited | Q3 2026 | -10.2 % | +200.0 % |
| Viatris Inc | Q2 2026 | +2.3 % | -0.2 % |
Sign in to see all peers for Puretech Health Plc.
Puretech Health Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Puretech Health Plc | - | - | - |
| Amgen Inc | 10.02% | 13.64% | 85.59% |
| Vertex Pharmaceuticals Inc | 14.16% | 16.63% | 20.08% |
| Argenx Se | 14.88% | 14.81% | 17.64% |
| Teva Pharmaceutical Industries Limited | 1.26% | 1.96% | 6.37% |
| Viatris Inc | - | - | - |
Sign in to see all peers for Puretech Health Plc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Puretech Health Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Puretech Health Plc | - | 90.99 |
| Amgen Inc | 26.97 | 6.53 |
| Vertex Pharmaceuticals Inc | 35.52 | 10.85 |
| Argenx Se | 49.17 | 7.56 |
| Teva Pharmaceutical Industries Limited | 57.55 | 3.63 |
| Viatris Inc | - | 1.62 |
| PEERS AVERAGE | 41.20 | 5.86 |
Sign in to see all peers for Puretech Health Plc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.